Regulation of Orofacial Movement: Amino Acid Mechanisms and Mutant Models

International Review of Neurobiology

Volumn 97, Issue , 2011, Pages 61-75

  Tomiyama, Katsunori ^a   O'Tuathaigh, Colm M P ^b,c   Waddington, John L ^b  

^a NIHON UNIVERSITY   (Japan)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

" Knockout" mice; Amino acids; GABA receptor subtypes; Glutamate receptor subtypes; Incisor movements; Jaw movements; Orofacial movements; Tongue movements

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BETA1A; 4 AMINOBUTYRIC ACID A RECEPTOR BETA1B; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BETA(1A,2); 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NEU DIFFERENTIATION FACTOR; NEUROTRANSMITTER; PHOSPHOLIPASE C RELATED CATALYTICALLY INACTIVE PROTEIN; PHOSPHOLIPASE C RELATED CATALYTICALLY INACTIVE PROTEIN 1; PHOSPHOLIPASE C RELATED CATALYTICALLY INACTIVE PROTEIN 2; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; BOOK; CATALYSIS; DRUG ACTIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; EFFERENT NERVE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MOTOR PERFORMANCE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OROFACIAL MOVEMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHIZOPHRENIA; SYNTHESIS; TRANQUILIZING ACTIVITY;

EID: 79959583045     PISSN: 00747742     EISSN: 00747742     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385198-7.00003-5     Document Type: Chapter

References (62)

1. Adachi K., Hasegawa M., Ikeda H., Sato M., Koshikawa N., Cools A.R. The superior colliculus contains a discrete region involved in the control of jaw movements: role of GABAA receptors. Eur. J. Pharmacol. 2003, 464:147-154.
2. Arias-Montaño J.A., Floran B., Floran L., Aceves J., Young J.M. Dopamine D (1) receptor facilitation of depolarization-induced release of gamma-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels. Synapse 2007, 61:310-319.
3. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:848-870.
4. Banerjee A., Macdonald M.L., Borgmann-Winter K.E., Hahn C.G. Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. Brain Res. Bull. 2010, 83:132-139.
5. Berthoud H.R. Neurochemical control and reconfiguration of the medullary network controlling different oromotor behaviors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R19-20.
6. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr. Bull. 2008, 34:806-812.
7. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., Sigmundsson A., Firth D.R., Nielsen B., Stefansdottir R., Novak T.J., Stefansson K., Gurney M.E., Andresson T. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J. Neurosci. 2007, 27:4519-4529.
8. Castner S.A., Williams G.V. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn. 2007, 63:94-122.
9. Chen Z.W., Olsen R.W. GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J. Neurochem. 2007, 100:279-294.
10. Collingridge G.L., Olsen R.W., Peters J., Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 2009, 56:2-5.
11. Desbonnet L., Waddington J.L., O'Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes? Behav. Brain Res. 2009, 204:258-273.
12. Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br. J. Pharmacol. 2010, 161:271-287.
13. Emson P.C. GABA (B) receptors: structure and function. Prog. Brain Res. 2007, 160:43-57.
14. Estep M.E. Modulation, adaptation, and control of orofacial pathways in healthy adults. J. Commun. Disord. 2009, 42:280-285.
15. Fabbrini G., Defazio G., Colosimo C., Thompson P.D., Berardelli A. Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment. Nat. Clin. Pract. Neurol. 2009, 5:93-105.
16. Goffin D., Aarum J., Schroeder J.E., Jovanovic J.N., Chuang T.T. D1-like dopamine receptors regulate GABAA receptor function to modulate hippocampal neural progenitor cell proliferation. J. Neurochem. 2008, 107:964-975.
17. Gong Y.G., Wu C.N., Xing Q.H., Zhao X.Z., Zhu J., He L. A two-method meta-analysis of Neuregulin 1 (NRG1) association and heterogeneity in schizophrenia. Schizophr. Res. 2009, 111:109-114.
18. Grimm J.W., See R.E. Chronic haloperidol-induced alterations in pallidal GABA and striatal D (1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience 2000, 100:507-514.
19. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gurm R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., Gallop R.J., Arnold S.E. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006, 12:824-828.
20. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 2006, 60:132-140.
21. Hernández-Echeagaray E., Cepeda C., Ariano M.A., Lobo M.K., Sibley D.R., Levine M.S. Dopamine reduction of GABA currents in striatal medium-sized spiny neurons is mediated principally by the D (1) receptor subtype. Neurochem. Res. 2007, 32:229-240.
22. Hikosaka O. GABAergic output of the basal ganglia. Prog. Brain Res. 2007, 160:209-226.
23. Inchul P., Amano N., Satoda T., Murata T., Kawagishi S., Yoshino K., Tanaka K. Control of oro-facio-lingual movements by the substantia nigra pars reticulata: high-frequency electrical microstimulation and GABA microinjection findings in rats. Neuroscience 2005, 134:677-689.
24. Inta D., Monyer H., Sprengel R., Meyer-Lindenberg A., Gass P. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci. Biobehav. Rev. 2010, 34:285-294.
25. Kanaani J., Kolibachuk J., Martinez H., Baekkeskov S. Two distinct mechanisms target GAD67 to vesicular pathways and presynaptic clusters. J. Cell Biol. 2010, 190:911-925.
26. Kanematsu T., Mizokami A., Watanabe K., Hirata M. Regulation of GABA (A)-receptor surface expression with special reference to the involvement of GABARAP (GABA (A) receptor-associated protein) and PRIP (phospholipase C-related, but catalytically inactive protein). J. Pharmacol. Sci. 2007, 104:285-292.
27. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull. 2010, 83:162-176.
28. Koshikawa N., Fujita S., Adachi K. Behavioral pharmacology of orofacial movement disorders. Int. Rev. Neurobiol 2011, in press.
29. Li B., Woo R.S., Mei L., Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
30. Lodge D. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 2009, 56:6-21.
31. Luo P., Zhang J., Yang R., Pendlebury W. Neuronal circuitry and synaptic organization of trigeminal proprioceptive afferents mediating tongue movement and jaw-tongue coordination via hypoglossal premotor neurons. Eur. J. Neurosci. 2006, 23:269-283.
32. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
33. Missale C., Fiorentini C., Collo G., Spano P. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J. Recept. Signal Transduct. Res. 2010, 30:347-354.
34. Mizokami A., Kanematsu T., Ishibashi H., Yamaguchi T., Tanida I., Takenaka K., Nakayama K.I., Fukami K., Takenawa T., Kominami E., Moss S.J., Yamamoto T., Nabekura J., Hirata M. Phospholipase C-related inactive protein is involved in trafficking of gamma2 subunit-containing GABA (A) receptors to the cell surface. J. Neurosci. 2007, 27:1692-1701.
35. Munafò M.R., Attwood A.S., Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr. Bull. 2008, 34:9-12.
36. Nakayama K. Role of the PLC-related, catalytically inactive protein p130 in GABA (A) receptor function. EMBO J. 2002, 21:1004-1011.
37. Nistri A., Ostroumov K., Sharifullina E., Taccola G. Tuning and playing a motor rhythm: how metabotropic glutamate receptors orchestrate generation of motor patterns in the mammalian central nervous system. J. Physiol. 2006, 572:323-334.
38. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
39. Olsen R.W., Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009, 56:141-148.
40. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol. Med. 2009, 39:1065-1076.
41. Peixoto M.F., Araújo N.P., Silva R.H., Castro J.P., Fukushiro D.F., Faria R.R., Zanier-Gomes P.H., Medrano W.A., Frussa-Filho R., Abílio V.C. Effects of gabaergic drugs on reserpine-induced oral dyskinesia. Behav. Brain Res. 2005, 160:51-59.
42. Pinard A., Seddik R., Bettler B. GABAB receptors: physiological functions and mechanisms of diversity. Adv. Pharmacol. 2010, 58:231-255.
43. Reynolds D.S. The value of genetic and pharmacological approaches to understanding the complexities of GABA (A) receptor subtype functions. Pharmacol. Biochem. Behav. 2008, 90:37-42.
44. Samadi P., Grégoire L., Morissette M., Calon F., Hadj Tahar A., Bélanger N., Dridi M., Bédard P.J., Di Paolo T. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 2008 a, 54:258-268.
45. Samadi P., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L.T., Bédard P.J., Di Paolo T. Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys. Synapse 2008 b, 62:101-109.
46. Sawczuk A., Mosier K.M. Neural control of tongue movement with respect to respiration and swallowing. Crit. Rev. Oral Biol. Med. 2001, 12:18-37.
47. Tomiyama K., McNamara F.N., Clifford J.J., Kinsella A., Koshikawa N., Waddington J.L. Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D (1)-like vs. D (2)-like receptor regulation. Eur. J. Pharmacol. 2001, 418:47-54.
48. Tomiyama K., McNamara F.N., Clifford J.J., Kinsella A., Drago J., Tighe O., Croke D.T., Koshikawa N., Waddington J.L. Phenotypic resolution of spontaneous and D (1)-like agonist-induced orofacial movement topographies in congenic dopamine D (1A) receptor 'knockout' mice. Neuropharmacology 2002, 42:644-652.
49. Tomiyama K., O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Lai D., Harvey R.P., Tighe O., Croke D.T., Koshikawa N., Waddington J.L. Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:330-333.
50. Tomiyama K., Song L., Kobayashi M., Kinsella A., Kanematsu T., Hirata M., Koshikawa N., Waddington J.L. Orofacial movements in phospholipase C-related catalytically inactive protein-1/2 double knockout mice: Effect of the GABAergic agent diazepam and the D (1) dopamine receptor agonist SKF 83959. Synapse 2010, 64:714-720.
51. Tomiyama K., Kim H., Kinsella A., Ehrlich M.E., Schütz G., Koshikawa N., Lawrence A.J., Waddington J.L., Drago J. Phenotypic disruption to orofacial movement topography in conditional mutants with generalised CamKIIa/Cre D1Tox vs striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells. Synapse 2011, in press.
52. Towers S.K., Hestrin S. D1-like dopamine receptor activation modulates GABAergic inhibition but not electrical coupling between neocortical fast-spiking interneurons. J. Neurosci 2008, 28:2633-2641.
53. Tsunekawa N., Arata A., Obata K. Development of spontaneous mouth/tongue movement and related neural activity, and their repression in fetal mice lacking glutamate decarboxylase 67. Eur. J. Neurosci. 2005, 21:173-178.
54. Uji A., Matsuda M., Kukita T., Maeda K., Kanematsu T., Hirata M. Molecules interacting with PRIP-2, a novel Ins (1,4,5) P3 binding protein type 2: Comparison with PRIP-1. Life Sci. 2002, 72:443-453.
55. Vicini S., Ortinski P. Genetic manipulations of GABAA receptor in mice make inhibition exciting. Pharmacol. Ther. 2004, 103:109-120.
56. Vigot R., Barbieri S., Bräuner-Osborne H., Turecek R., Shigemoto R., Zhang Y.P., Luján R., Jacobson L.H., Biermann B., Fritschy J.M., Vacher C.M., Müller M., Sansig G., Guetg N., Cryan J.F., Kaupmann K., Gassmann M., Oertner T.G., Bettler B. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 2006, 50:589-601.
57. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., O'Boyle K.M. Behavioral pharmacology of 'D1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:811-831.
58. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 2005, 181:611-638.
59. Waddington J.L., O'Sullivan G.J., Tomiyama K. Regulation of orofacial movement: dopamine receptor mechanisms and mutant models. Int. Rev. Neurobiol 2011, in press.
60. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
61. Walls A.B., Nilsen L.H., Eyjolfsson E.M., Vestergaard H.T., Hansen S.L., Schousboe A., Sonnewald U., Waagepetersen H.S. GAD65 is essential for synthesis of GABA destined for tonic inhibition regulating epileptiform activity. J. Neurochem. 2010, 115:1398-1408.
62. Whitty P., Owoeye O., Waddington J.L. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr. Bull. 2009, 35:415-424.